JP2024516795A5 - - Google Patents
Info
- Publication number
- JP2024516795A5 JP2024516795A5 JP2023562510A JP2023562510A JP2024516795A5 JP 2024516795 A5 JP2024516795 A5 JP 2024516795A5 JP 2023562510 A JP2023562510 A JP 2023562510A JP 2023562510 A JP2023562510 A JP 2023562510A JP 2024516795 A5 JP2024516795 A5 JP 2024516795A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- everolimus
- amsenestrant
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315063 | 2021-04-12 | ||
| EP21315063.4 | 2021-04-12 | ||
| PCT/EP2022/059704 WO2022218958A1 (en) | 2021-04-12 | 2022-04-12 | Combination comprising everolimus and amcenestrant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516795A JP2024516795A (ja) | 2024-04-17 |
| JP2024516795A5 true JP2024516795A5 (enExample) | 2025-04-16 |
Family
ID=75825773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562510A Pending JP2024516795A (ja) | 2021-04-12 | 2022-04-12 | エベロリムスおよびアムセネストラントを含む組合せ物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240197692A1 (enExample) |
| EP (1) | EP4322942B1 (enExample) |
| JP (1) | JP2024516795A (enExample) |
| CN (1) | CN117177743A (enExample) |
| AR (1) | AR125330A1 (enExample) |
| ES (1) | ES3036485T3 (enExample) |
| TW (1) | TW202304424A (enExample) |
| WO (1) | WO2022218958A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3847157T3 (da) | 2018-09-07 | 2022-08-08 | Sanofi Sa | Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772247A2 (en) * | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| SG11201806829TA (en) * | 2016-02-15 | 2018-09-27 | Sanofi Sa | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
| EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| MX2022010425A (es) * | 2020-03-06 | 2022-09-07 | Olema Pharmaceuticals Inc | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. |
-
2022
- 2022-04-08 TW TW111113410A patent/TW202304424A/zh unknown
- 2022-04-11 AR ARP220100914A patent/AR125330A1/es not_active Application Discontinuation
- 2022-04-12 EP EP22722256.9A patent/EP4322942B1/en active Active
- 2022-04-12 US US18/286,496 patent/US20240197692A1/en active Pending
- 2022-04-12 JP JP2023562510A patent/JP2024516795A/ja active Pending
- 2022-04-12 CN CN202280027705.5A patent/CN117177743A/zh active Pending
- 2022-04-12 WO PCT/EP2022/059704 patent/WO2022218958A1/en not_active Ceased
- 2022-04-12 ES ES22722256T patent/ES3036485T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516363A5 (enExample) | ||
| JP2023550149A5 (enExample) | ||
| JP2023516951A5 (enExample) | ||
| JP2024507938A5 (enExample) | ||
| JP2023503309A5 (enExample) | ||
| JP2023541432A5 (enExample) | ||
| RU2020107416A (ru) | Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| JP2020521797A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| AR125330A1 (es) | Combinación que comprende everolimus y amcenestrant | |
| JP2016502981A5 (enExample) | ||
| JP6063550B2 (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| JP2013518124A5 (enExample) | ||
| RU2019130325A (ru) | ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ | |
| MX2014002663A (es) | Nuevo esquema de administracion de la n-hidroxi-4-{2-[3-(n,n-dimet ilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida. | |
| JP2021522246A5 (enExample) | ||
| JP2008517991A5 (enExample) | ||
| JP2025511402A5 (enExample) | ||
| JP2024540439A5 (enExample) | ||
| JPWO2021206167A5 (enExample) | ||
| RU2013149635A (ru) | Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря |